Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT 1 receptor antagonists

European Journal of Medicinal Chemistry

Volumn 49, Issue , 2012, Pages 183-190

  Wang, Jin Liang ^a   Zhang, Jun ^a   Zhou, Zhi Ming ^a   Li, Zhi Huai ^a   Xue, Wei Zhe ^a   Xu, Di ^a   Hao, Li Ping ^a   Han, Xiao Feng ^a   Fei, Fan ^a   Liu, Ting ^b   Liang, Ai Hua ^b  

^a BEIJING INSTITUTE OF TECHNOLOGY   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Aminocarbonyl benzimidazole; Angiotensin II AT 1 receptor antagonists; Hypertension

Indexed keywords

4 METHYL 2 PROPYL 1H BENZIMIDAZOLE 6 CARBOXYLIC CHLORIDE; 4' [(4 METHYL 6 2' METHOXY BENZYLAMINOCARBOXYL 2 PROPYL 1H BENZIMIDAZOLYL)METHYL] 2 BIPHENYL CARBOXYLIC ACID; 4' [(4 METHYL 6 3' METHOXYBENZYLAMINOCARBOXYL 2 PROPYL 1H BENZIMIDAZOLYL)METHYL] 2 BIPHENYLCARBOXYLIC ACID; 4' [(4 METHYL 6 4' METHOXYBENZYLAMINOCARBOXYL 2 PROPYL 1H BENZIMIDAZOLYL)METHYL] 2 BIPHENYL CARBOXYLIC ACID; 4' [(6 3',4' DIMETHOXYBENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL)METHYL] 2 BIPHENYL CARBOXYLIC ACID; 4' [(6 BENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL)METHYL] 2 BIPHENYL CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; METHYL 4' [(6 BENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL)METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (2' FLUORO)PHENETHYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (2' METHOXY)BENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (2',5' DIMETHOXY)PHENETHYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (3' METHOXY)BENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (3' METHOXY)PHENETHYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (3',4' DIMETHOXY)BENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (3',4' DIMETHOXY)PHENETHYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (4' FLUORO)PHENETHYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (4' METHOXY)BENZYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; METHYL 4' [[6 (4' METHOXY)PHENETHYLAMINOCARBOXYL 4 METHYL 2 PROPYL 1H BENZIMIDAZOLYL]METHYL]BIPHENYL 2 CARBOXYLATE; N (2 FLUOROPHENETHYL[(4 METHYL 2 PROPYL 1H BENZIMIDAZOLE)6 YL]AMIDE; N (2 METHOXYBENZYL) [4 METHYL 2 PROPYL 1H BENZIMIDAZOLE) 6 YL]AMIDE; N (2,5 DIMETHOXYPHENETHYL) [(4 METHYL 2 PROPYL 1H BENZIMIDAZOLE)6 YL]AMIDE; N (3 METHOXYBENZYL) [4 METHYL 2 PROPYL 1H BENZIMIDAZOLE) 6 YL]AMIDE; N (3 METHOXYPHENETHYL) [(4 METHYL 2 PROPYL 1H BENZIMIDAZOLE)6 YL]AMIDE; N (3,4 DIMETHOXY BENZYL) [4 METHYL 2 PROPYL 1H BENZIMIDAZOLE) 6 YL]AMIDE; N (3,4 DIMETHOXYPHENETHYL) [(4 METHYL 2 PROPYL 1H BENZIMIDAZOLE)6 YL]AMIDE; N (4 FLUOROPHENETHYL[(4 METHYL 2 PROPYL 1H BENZIMIDAZOLE) 6 YL]AMIDE; N (4 METHOXY BENZYL) [4 METHYL 2 PROPYL 1H BENZIMIDAZOLE) 6 YL]AMIDE; N BENZYL [(4 METHYL 2 PROPYL 1H BENZIMIDAZOLE) 6 YL]AMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESSENTIAL HYPERTENSION; FUNCTION TEST; INFRARED SPECTROSCOPY; MALE; MOLECULAR MODEL; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; DRUG DESIGN; MODELS, MOLECULAR; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84862830267     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.01.009     Document Type: Article

References (34)

1. 1 receptor antagonists: clinical implications of active metabolites J. Med. Chem. 46 2003 2261 2270 (Pubitemid 36637909)
2. T.L. Goodfriend, M.E. Elliott, and K.J. Catt Drug therapy: angiotensin receptors and their antagonists N. Engl. J. Med. 334 1996 1649 1655
3. G.K.Aulakh, R.K.Sodhi, and M. Singh An update on non-peptide angiotensin receptor antagonists and related RAAS modulators Life Sci. 81 2007 615 639 (Pubitemid 47271905)
4. J.D. Irvin, and J.M. Viau Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril Am. J. Med. 81 suppl 4C 1986 46 50
5. Y. Lacourciere, and J. Lefebvre Cough induced by pharmacological modulation of the rennin-angiotensin-aldosterone system. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists N.S. Dhalla, P. Zahradka, I.M.C. Dixon, R.E. Beamish, Angiotensin II Receptor Blockade: Physiological and Clinical Implications 1998 Kluwer Academic publishers Boston 115 125
6. M.A. Creager, L. Joseph, and J.D. Victor Vascular Medicine: A Companion to Braunwald's Heart Disease 2006 Saunders Philadelphia
7. Y. Furukawa, S. Kishimoto, K. Nishikawa, Hypotensive Imidazole Derivatives, U.S. 4340598, 1982.
8. D.J. Carini, J.V. Duncia, P.E. Aldrich, A.T. Chiu, A.L. Johnson, M.E. Pierce, W.A. Price, J.B. Santella, G.J. Wells, R.R. Wexler, P.C. Wong, S.-E. Yoo, and P.B.M.W.M. Timmermans Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives J. Med. Chem. 34 1991 2525 2547
9. K. Kubo, Y. Kohara, E. Imamiya, Y. Sugiura, Y. Inada, Y. Furukawa, K. Nishikawa, and T. Nakat Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazole carboxylic acids J. Med. Chem. 36 1993 2182 2195 (Pubitemid 23241152)
10. U.J. Ries, G. Mihm, B. Narr, K.M. Hasselbach, H. Wittneben, M. Entzeroth, J.C.A. van Meel, W. Wienen, and N.H. Hauel 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships J. Med. Chem. 36 1993 4040 4051 (Pubitemid 24024676)
11. B. Ferrari, J. Taillades, P. Perreaut, C. Bernhart, J. Gougat, P. Guiraudou, C. Cazaubon, A. Roccon, D. Nisato, G. Le Fur, and J.C. Brelire Development of tetrazole bioisosteres in angiotensin II antagonists Bioorg. Med. Chem. Lett. 4 1994 45 50 (Pubitemid 24128684)
12. J.A. Brousil, and J.M. Burke Olmesartan medoxomil: an angiotensin II-receptor blocker Clin. Ther. 25 2003 1041 1055 (Pubitemid 36532577)
13. A. Bali, Y. Bansal, M. Sugumaran, J.S. Saggu, P. Balakumar, G. Kaur, G. Bansal, A. Sharmac, and M. Singh Design, synthesis, and evaluation of novelly substituted benzimidazole compounds as angiotensin II receptor antagonists Bioorg. Med. Chem. Lett. 15 2005 3962 3965 (Pubitemid 41095502)
14. 1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives Eur. J. Med. Chem. 43 2008 1808 1812
15. N. Kaur, A. Kaur, Y. Bansal, D.I. Shah, G. Bansal, and M. Singh Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists Bioorg. Med. Chem. 16 2008 10210 10215 (Pubitemid 50331575)
16. W.-F. Yu, Z.-M. Zhi, H.-B. Zhu, and L.-S. He Synthesis of telmisartan and its derivatives and evaluation of their biological activities Chin. J. Org. Chem. 36 2006 318 323 (Pubitemid 43723486)
17. Full crystallographic details of 5e have been deposited with the Cambridge Crystallographic Data Centre and allocated the deposition number CCDC 818973. Copies of the data can be obtained, free of charge, on application to The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: +44 1223336 033; e-mail: deposit@ccdc.cam.ac.uk or www.ccdc.cam.ac.uk).
18. H.Yanagisawa, Y. Amemiya, T. Kanazaki, Y. Shimoji, K. Fujimoto, Y. Kitahara, T. Sada, M. Mizuno, M. Ikeda, S. Miyamoto, Y. Furukawa, and H. Koike Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds J. Med. Chem. 39 1996 323 338
19. 1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems J. Med. Chem. 51 2008 2137 2146 (Pubitemid 351503269)
20. K.M. Gough, K. Belohorcová, and K. Kaiser Quantitative structure-activity relationships (QSARs) of Photobacterium phosphoreum toxicity of nitrobenzene derivatives Sci. Total Environ. 142 1994 179 190 (Pubitemid 24081178)
21. Discovery Studio, 2.0 Version. Accelrys 2005
22. 1 Receptor Antagonists J. Med. Chem. 49 2006 1526 1535 (Pubitemid 43376500)
23. E.M. Krovat, and T. Langer Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification J. Med. Chem. 46 2003 716 726 (Pubitemid 36258863)
24. H.-Y. Wang, L.-L. Li, Z.-X. Cao, S.-D. Luo, Y.-Q. Wei, and S.-Y. Yang A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it Chem. Bio. Drug Des 73 2009 115 126
25. E.M. David, N.S. Tonous, and K.P. Michael A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker J. Cardiovasc. Pharmacol. 46 2005 585 593
26. Y. Kohara, K. Kubo, E. Imamiya, T. Wada, Y. Inada, and T. Naka Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres J. Med. Chem. 39 1996 5228 5235 (Pubitemid 27010313)
27. 1 angiotensin II receptor antagonists based on the 4-phenylquinoline structure J. Med. Chem. 47 2004 2574 2586 (Pubitemid 38580094)
28. 1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds J. Med. Chem. 49 2006 6451 6464 (Pubitemid 44657441)
29. 1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis J. Med. Chem. 49 2006 4305 4316 (Pubitemid 44036674)
30. H. Sanderson, and M. Thomsen Comparative analysis of pharmaceuticals versus industrial chemicals acute aquatic toxicity classification according to the United Nations classification system for chemicals. Assessment of the (Q)SAR predictability of pharmaceuticals acute aquatic toxicity and their predominant acute toxic mode-of-action Toxicol. Lett. 187 2009 84 93
31. M.J. Robertoson, M.P. Cunoosamy, and K.L. Clark Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta Br. J. Pharmacol. 106 1992 166 172
32. H.O. Schild PA, A new scale for the measurement of drug antagonism Br. J. Pharmacol. 2 1947 189 205
33. K. Kubo, Y. Inada, Y. Kohara, Y. Sugiura, M. Ojima, K. Itoh, Y. Furukawa, K. Nishikawa, and T. Naka Nonpeptide angiotensin II receptor antagonists. synthesis and biological activity of benzimidazoles J. Med. Chem. 36 1993 1772 1784 (Pubitemid 23191305)
34. H.A. Raul, Y.M.C. Violeta, P.M. Sandra, J.F. Francisco, A.F.S. Cesar, B. Victor, I.B. Hiram, and S.Z.R. Luis Molecular design and QSAR study of low acute toxicity biocides with 4,4′-dimorpholylmethane core obtained by microwave-assisted synthesis Green Chem. 12 2010 1036 1048